|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...2728293031323334353637...6566» |
- ||| Trial completion, Trial primary completion date: A Clinical Challenge Study of BCG in Healthy Volunteers (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=52, Completed, Sponsor: University of Oxford
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Jan 2015
- | Baxdela (delafloxacin) / Menarini, Melinta Therap
Enrollment change, Trial termination: Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea (clinicaltrials.gov) - Jan 20, 2015
P3, N=460, Terminated, Sponsor: Melinta Therapeutics, Inc.
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Jan 2015 N=757 --> 460 | Active, not recruiting --> Terminated
- ||| Nontuberculous mycobacteria: Diagnostic Accuracy of Nontuberculous Mycobacterial Lung Disease Based on Chest CT (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=124, Active, not recruiting, Sponsor: Seoul National University Hospital
- ||| Trial completion, Enrollment change, Trial primary completion date: Impact of PCV on Disease and Colonization Among Native American Communities (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=6628, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
N=757 --> 460 | Active, not recruiting --> Terminated Recruiting --> Completed | N=3600 --> 6628 | Trial primary completion date: Jun 2013 --> Apr 2012
- |||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Trial primary completion date: Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) (clinicaltrials.gov) - Jan 15, 2015
P3, N=566, Recruiting, Sponsor: Bayer
Recruiting --> Completed | N=3600 --> 6628 | Trial primary completion date: Jun 2013 --> Apr 2012 Trial primary completion date: Nov 2015 --> Feb 2016
- Clinical: Causes of Fever in Bangladeshi Patients (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=330, Recruiting, Sponsor: University of Oxford
- || Enrollment closed, Trial primary completion date: Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: American University of Beirut Medical Center
Trial primary completion date: Nov 2015 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> May 2014
- || Trial completion, Trial primary completion date: Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion (clinicaltrials.gov) - Jan 15, 2015
P2/3, N=24, Completed, Sponsor: Atlantia Food Clinical Trials
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> May 2014 Recruiting --> Completed | Trial primary completion date: May 2014 --> Dec 2014
- bismuth subcitrate potassium/ metronidazole/tetracycline / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: An Open-Label Trial Of Reduced- Dose Pylera, Amoxicillin, and Esomeprazole in the Treatment Of Helicobacter Pylori Infection (clinicaltrials.gov) - Jan 15, 2015
P4, N=0, Withdrawn, Sponsor: American University of Beirut Medical Center
Recruiting --> Completed | Trial primary completion date: May 2014 --> Dec 2014 N=100 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2014 --> Jul 2016
- Trial primary completion date, Gram negative: Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=400, Recruiting, Sponsor: Rabin Medical Center
N=100 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2014 --> Jul 2016 Trial primary completion date: Jan 2015 --> Jan 2017
- meropenem / Generic mfg., colistin sulphate / Generic mfg.
Trial primary completion date: Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem (clinicaltrials.gov) - Jan 13, 2015
P4, N=360, Recruiting, Sponsor: Mical Paul
Trial primary completion date: Jan 2015 --> Jan 2017 Trial primary completion date: Jan 2016 --> Jun 2016
- |||||| New P2b trial: Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 (clinicaltrials.gov) - Jan 13, 2015
P2b, N=192, Enrolling by invitation, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- ||||||| ceftriaxone / Generic mfg., ceftaroline fosamil / Generic mfg.
Trial completion: Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) (clinicaltrials.gov) - Jan 13, 2015
P2/3, N=161, Completed, Sponsor: Cerexa, Inc.
Trial primary completion date: Jan 2016 --> Jun 2016 Active, not recruiting --> Completed
- Arikace (amikacin liposome inhalation suspension) / Insmed
Enrollment change, Trial withdrawal: Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - Jan 12, 2015
P3, N=0, Withdrawn, Sponsor: Insmed Incorporated
Active, not recruiting --> Completed N=300 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment closed: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Jan 12, 2015
P3, N=688, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
N=300 --> 0 | Not yet recruiting --> Withdrawn Enrolling by invitation --> Active, not recruiting
- ||||| New P1/2 trial: Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess (clinicaltrials.gov) - Jan 8, 2015
P1/2, N=100, Not yet recruiting, Sponsor: Eastern Virginia Medical School
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment closed: Efficacy of Rifaximin in Preventing Campylobacteriosis (clinicaltrials.gov) - Jan 8, 2015
P2/3, N=28, Active, not recruiting, Sponsor: Johns Hopkins Bloomberg School of Public Health
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (clinicaltrials.gov) - Jan 7, 2015
P3, N=588, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2009 --> Jun 2008
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants (clinicaltrials.gov) - Jan 7, 2015
P3, N=807, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Apr 2009 --> Jun 2008 Trial primary completion date: Mar 2008 --> May 2007
- Trial completion, Enrollment change, Trial primary completion date: Gene Xpert Diagnosis of TB Using Tracheal Aspirates From Intensive Care Unit (ICU) Patients (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=341, Completed, Sponsor: University of Cape Town
Trial primary completion date: Mar 2008 --> May 2007 Recruiting --> Completed | N=150 --> 341 | Trial primary completion date: Apr 2012 --> Jul 2013
- Trial completion: StaphCI: Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=195, Completed, Sponsor: University Hospital Muenster
Recruiting --> Completed | N=150 --> 341 | Trial primary completion date: Apr 2012 --> Jul 2013 Active, not recruiting --> Completed
- |||| Enrollment open: A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) (clinicaltrials.gov) - Jan 7, 2015
P2, N=83, Recruiting, Sponsor: Global Alliance for TB Drug Development
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Enrollment closed: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. (clinicaltrials.gov) - Jan 7, 2015
P3, N=240, Active, not recruiting, Sponsor: Novartis
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Arbelic (telavancin) / Cumberland
Enrollment open: Telavancin Observational Use Registry (TOUR) (clinicaltrials.gov) - Jan 6, 2015
P=N/A, N=1000, Recruiting, Sponsor: Theravance Biopharma Antibiotics, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Onbrez (indacaterol) / Novartis
Trial completion: INFINITY: Indacaterol EfectIveness In COPD Patients With Tuberculosis History (clinicaltrials.gov) - Jan 5, 2015
P3, N=135, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| New P2a trial: Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 (clinicaltrials.gov) - Jan 2, 2015
P2a, N=144, Completed, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- New P1 trial, HEOR: Hyperbaric Oxygen Therapy in Diabetics With Chronic Foot Ulcers and Improvement of Quality of Life (clinicaltrials.gov) - Jan 2, 2015
P1, N=38, Completed, Sponsor: Chen-Yu Chen
- |||||| Enrollment open: Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ. (clinicaltrials.gov) - Jan 1, 2015
P3, N=55, Recruiting, Sponsor: Novartis
Recruiting --> Completed Not yet recruiting --> Recruiting
- | lignocaine / Generic mfg.
Trial completion: A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=500, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Trial completion: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years (clinicaltrials.gov) - Dec 30, 2014
P3b, N=1407, Completed, Sponsor: Novartis Vaccines
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, Trial initiation date: Iron Absorption and Utilization During Tuberculosis and After Treatment (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=18, Not yet recruiting, Sponsor: Swiss Federal Institute of Technology
Active, not recruiting --> Completed N=48 --> 18 | Initiation date: Aug 2014 --> Mar 2015
- ||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Trial completion: Safety of MenACWY-CRM Vaccination in Adolescents (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=55429, Completed, Sponsor: Novartis Vaccines
N=48 --> 18 | Initiation date: Aug 2014 --> Mar 2015 Active, not recruiting --> Completed
- ||||||| Trial completion, Enrollment change: Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children (clinicaltrials.gov) - Dec 24, 2014
P3, N=426, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Recruiting --> Completed | N=660 --> 426
- | Trial completion: Leprosy Skin Test Antigens Trial (clinicaltrials.gov) - Dec 22, 2014
P2, N=260, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=660 --> 426 Recruiting --> Completed
- prednisone / Generic mfg.
Trial primary completion date: Pred-ART: Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone (clinicaltrials.gov) - Dec 19, 2014
P3, N=240, Recruiting, Sponsor: University of Cape Town
Recruiting --> Completed Trial primary completion date: Feb 2015 --> Dec 2015
- Trial primary completion date: Cepheid Rectal Sample Validation Study (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=550, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Feb 2015 --> Dec 2015 Trial primary completion date: Nov 2014 --> Feb 2015
- Trial completion: Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults (clinicaltrials.gov) - Dec 17, 2014
P1, N=30, Completed, Sponsor: University of Oxford
Trial primary completion date: Nov 2014 --> Feb 2015 Active, not recruiting --> Completed
- ||||||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi, Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Trial completion: Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) (clinicaltrials.gov) - Dec 13, 2014
P3, N=385, Completed, Sponsor: Sanofi Pasteur MSD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- phenoxymethylpenicillin / Generic mfg., doxycycline / Generic mfg., amoxicillin / Generic mfg.
Trial completion: NorTick_EM: Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (clinicaltrials.gov) - Dec 13, 2014
P4, N=225, Completed, Sponsor: Morten Lindbaek
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date: Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults (clinicaltrials.gov) - Dec 13, 2014
P1, N=52, Active, not recruiting, Sponsor: Novartis
Active, not recruiting --> Completed Trial primary completion date: Nov 2014 --> May 2015
- Trial primary completion date: A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. (clinicaltrials.gov) - Dec 13, 2014
P1, N=50, Active, not recruiting, Sponsor: Novartis
Trial primary completion date: Nov 2014 --> May 2015 Trial primary completion date: Nov 2014 --> Apr 2015
- | nacubactam (RG6080) / Roche, Meiji Seika
Trial completion: A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595 (clinicaltrials.gov) - Dec 13, 2014
P1, N=40, Completed, Sponsor: Meiji Seika Pharma Co., Ltd.
Trial primary completion date: Nov 2014 --> Apr 2015 Active, not recruiting --> Completed
- azithromycin / Generic mfg.
Enrollment change, Trial withdrawal: Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection (clinicaltrials.gov) - Dec 12, 2014
P3, N=0, Withdrawn, Sponsor: Adapt Produtos Oftalmol
Active, not recruiting --> Completed N=60 --> 0 | Not yet recruiting --> Withdrawn
- New P1 trial: LACRING01: Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis (clinicaltrials.gov) - Dec 11, 2014
P1, N=6, Recruiting, Sponsor: University Ghent
- |||| MenABCWY vaccine (GSK3536819A) / GSK
Enrollment open: Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents (clinicaltrials.gov) - Dec 10, 2014
P2, N=240, Recruiting, Sponsor: Novartis Vaccines
N=60 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- atopaxar (E5555) / Eisai
Trial completion, Trial primary completion date: WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jul 2014
- Trial completion, Trial initiation date: Exogenous Reinfection of Tuberculosis in Taiwan (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=150, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jul 2014 Recruiting --> Completed | Initiation date: Jan 1999 --> Aug 2005
- | New P2 trial, Combination therapy: Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis (clinicaltrials.gov) - Dec 10, 2014
P2, N=253, Completed, Sponsor: Shanghai University of Traditional Chinese Medicine
- Trial completion, Trial primary completion date: Risk Assessment of Long-Haul Truck Drivers (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=294, Completed, Sponsor: Wake Forest School of Medicine
Recruiting --> Completed | Initiation date: Jan 1999 --> Aug 2005 Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Mar 2010
- colistin sulphate / Generic mfg.
Trial primary completion date: Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036) (clinicaltrials.gov) - Dec 9, 2014
P=N/A, N=10, Active, not recruiting, Sponsor: University of Pittsburgh
Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Mar 2010 Trial primary completion date: Aug 2013 --> Dec 2014